이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

NHL/CLL 환자의 huCART19-IL18

2026년 11월 11일 업데이트: University of Pennsylvania

재발성 또는 불응성 CD19+ 비호지킨 림프종(NHL) 및 만성 림프구성 백혈병(CLL) 환자에서 huCART19-IL18 세포의 I상 시험

The purpose of this study is to evaluate the safety and feasibility of huCART19-IL18 cells in patients with relapsed or refractory CD19+ cancers.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

This is a Phase I study to assess the safety, tolerability, manufacturing feasibility, pharmacokinetics, and preliminary efficacy of huCART19-IL18 cells in patients with CD19+ cancers. The study will take place in two parts: an initial Dose-Finding Phase and an Expansion Phase. In the dose-finding phase, the maximum tolerated dose will be determined using a Bayesian Optimal Interval (BOIN) design within each of the following disease-specific cohorts:

  • Cohort A: Non-Hodgkin Lymphoma (Active, Not Recruiting)
  • Cohort B: Chronic Lymphocytic Leukemia (Active, Not Recruiting)
  • Cohort C: Acute Lymphoblastic Leukemia (Active, Not Recruiting)
  • Cohort D (Expansion Phase): Non Hodgkin Lymphoma and Acute Lymphoblastic Leukemia (Active, Not Recruiting) will evaluate changes to cell activation method in the huCART19-IL18 manufacturing process using the recommended dose for expansion (RDE) arising out of the dose-finding phase.

연구 유형

중재적

등록 (추정된)

72

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19104
        • University of Pennsylvania

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Signed informed consent form

  2. Documentation of CD19 expression on malignant cells by flow cytometry/IHC from a CLIA certified laboratory

    NHL Patients: Within 6 months of physician-investigator confirmation of eligibility as long as there has been no intervening CD19 directed therapy since expression confirmed. Results outside of this window may be used, if there is no accessible tumor site and the subject did not receive intervening CD19 directed therapy since CD19 expression was confirmed.

    CLL and ALL Patients: At time of most recent relapse. If the subject has subsequently received CD19-directed therapy since this result was obtained, repeating testing must be performed to determine eligibility.

  3. Patients with relapsed disease after prior allogeneic SCT must meet the following criteria:

    a. Have no active GVHD and require no immunosuppression b. Are more than 6 months from transplant at the time of physician-investigator confirmation of eligibility

  4. Adequate organ function defined as:

    a. Creatinine ≤ 1.6 mg/dl b. ALT/AST ≤ 3x upper limit of normal range c. Direct bilirubin ≤ 2.0 mg/dl, unless the subject has Gilbert's syndrome (≤3.0 mg/dl) d. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen > 92% on room air e. Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO/MUGA

  5. Evidence of active disease within 12 weeks of physician-investigator confirmation of eligibility. .

  6. Male or female age ≥ 18 years.

  7. ECOG Performance Status that is either 0 or 1.

  8. Subjects of reproductive potential must agree to use acceptable birth control methods.

  9. Disease-specific criteria:

NHL Patients (Cohorts A and D):

i. Patients with any of the following diagnoses: Diffuse Large B-cell Lymphoma not otherwise specified (DLBCL NOS), germinal center or activated B-cell types;Primary Cutaneous DLBCL; Primary Mediastinal (thymic) Large B-cell Lymphoma; ALK+ Anaplastic Large B-cell Lymphoma; High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangements (i.e., "Double or Triple Hit"); High-grade B-cell Lymphoma, NOS; T-cell Rich B-cell Lymphoma; Transformed Follicular Lymphoma; or any aggressive B-cell lymphoma arising from indolent lymphoma.

1. Patients must have either relapsed after, or be ineligible for, prior CAR T cell therapy, and meet one of the following criteria:

  1. Relapsed/refractory disease after at least 2 prior lines of appropriate therapy; OR

  2. Relapsed/refractory disease after autologous SCT; OR

  3. Relapsed/refractory disease after allogeneic SCT. ii. Follicular lymphoma

    1. Patients must have either relapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND
    2. Received at least 2 prior lines of appropriate therapy (not including single agent monoclonal antibody therapy) and progressed within 2 years after second or higher line of therapy.

iii. Mantle cell lymphoma

  1. Patients must have either failed standard of care CAR T cell therapy (e.g., Tecartus™, etc) or other investigational CAR T cell product, OR be ineligible for standard of care Tecartus™; and

  2. Patients must also meet one of the following criteria:

    1. Relapsed/refractory disease after at least 2 prior lines of appropriate therapy, including a BTK inhibitor. Single-agent monoclonal antibody therapy does not count towards prior lines of therapy; OR
    2. Relapsed/refractory disease after prior autologous SCT; OR
    3. Relapsed/refractory disease after prior allogeneic SCT.

CLL Patients (Cohort B):

i. Chronic Lymphocytic Leukemia

  1. Patients with relapsed/refractory disease after at least 2 prior lines of appropriate therapy; AND
  2. Patients must have previously received or be intolerant to an approved BTK inhibitor and venetoclax, unless a BTK inhibitor or venetoclax is contraindicated.

ii. Large cell transformation of CLL (Richter's Transformation)

1. Patients must be primary refractory or received at least 1 prior line of treatment for Richter's Transformation.

c. ALL Patients (Cohorts C and D): i. Patients with b-cell acute lymphoblastic leukemia. Note: Chronic myeloid leukemia (CML) lymphoid blast crisis is considered a sub-type of relapsed B-ALL, thus will be encompassed in our definition of B-ALL throughout; AND ii. Patients with 2nd or greater relapse or refractory disease as defined by one of the following criteria:

  1. Recurrent disease in the blood or bone marrow identified morphologically, by IHC or flow; OR

  2. Isolated CNS disease. Note: Patients with prior/current history of CNS3 disease will only be eligible for treatment if the CNS disease is responsive to therapy; OR

  3. Recurrent extramedullary disease at other (non-CNS) sites if disease response can be assessed radiographically. Note: Patients with recurrent extramedullary disease do not need to have detectable blood or bone marrow involvement; OR

  4. Any relapse after allogeneic SCT; OR

  5. Patients with refractory disease as defined by one of the following:

    1. Failure to achieve remission (<5% bone marrow blasts or ongoing extramedullary or CNS disease) after 2 cycles of induction chemotherapy; OR
    2. Patients that achieve remission but remain MRD+ after ≥2 cycles of induction chemotherapy.

Exclusion Criteria:

  1. Active hepatitis B, active hepatitis C, or other active, uncontrolled infection.

  2. Class III/IV cardiovascular disability according to the New York Heart Association Classification.

  3. Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.

  4. Active acute or chronic GVHD requiring systemic therapy.

  5. Dependence on systemic steroids or immunosuppressant medications. For additional details regarding use of steroid and immunosuppressant medications.

  6. RETIRED WITH PROTOCOL AMENDMENT V7

  7. Receipt of prior huCART19 therapy.

  8. CNS disease as defined by disease-cohort as follows:

    1. NHL/CLL Patients: Active CNS disease. Note: Patients with a history of CNS involvement that was successfully treated are eligible. A CNS evaluation is only required for eligibility if a subject is experiencing signs/symptoms of CNS involvement.
    2. ALL Patients: CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity.
  9. Pregnant or nursing (lactating) women.

  10. Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to their cancer or previous cancer treatment.

  11. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort A: NHL Dose Level 1a (DL1a)

3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort A: NHL Dose Level -1 (DL-1)

7x10^5 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 1a.

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort A: NHL Dose Level 1b (DL1b)

3x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort A: NHL Dose Level 2 (DL2)

7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort A: NHL Dose Level 3 (DL3)

3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort A: NHL Dose Level 4 (DL4)

7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort A: NHL Dose Level 5 (DL5)

3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort B: CLL Dose Level 1b (DL1b)

3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 2.

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort B: CLL Dose Level 2 (DL2)

7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort B: CLL Dose Level 3 (DL3)

3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort B: CLL Dose Level 4 (DL4)

7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort B: CLL Dose Level 5 (DL5)

3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort C: ALL Dose Level 1b (DL1b)

3x10^6 huCART19-IL18 cells administered as a single intravenous (IV) infusion or slow IV push; This dose level will only be explored if at least one DLT is observed at Dose Level 2.

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort C: ALL Dose Level 2 (DL2)

7x10^6 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort C: ALL Dose Level 3 (DL3)

3x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort C: ALL Dose Level 4 (DL4)

7x10^7 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort C: ALL Dose Level 5 (DL5)

3x10^8 huCART19-IL18 cells following lymphodepleting chemotherapy administered as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort D: NHL

7x10^6 huCART19-IL18 as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

실험적: Cohort D: ALL

7x10^6 huCART19-IL18 as a single intravenous (IV) infusion or slow IV push

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0
기간: Up to 15 years post-huCART19-IL18 infusion

Cohorts A-C: Type, frequency and severity of adverse events as assessed by CTCAE V5.0. Each disease-specific cohort will be analyzed separately.

Up to 15 years post-huCART19-IL18 infusion
Occurrence of dose-limiting toxicities (DLTs)
기간: 28 days post-huCART19-IL18 infusion

Cohorts A-C: Unacceptable toxicity as defined by the protocol. DLTs will be evaluated separately by each disease-specific cohort.

28 days post-huCART19-IL18 infusion
Determination of Maximum Tolerated Dose (MTD)
기간: 28 days post-huCART19-IL18 infusion

Cohorts A-C: Selected based on an isotonic regression model. The MTD will be established separately by disease-specific cohort.

28 days post-huCART19-IL18 infusion
Determination of a recommended dose for expansion (RDE)
기간: 3 months post-huCART19-IL18 infusion

Cohorts A-C: Evaluated by Cohort/dose level using a multi-criteria decision analysis.

3 months post-huCART19-IL18 infusion
Proportion of manufactured products that meet the product release criteria
기간: 3 months

Cohort D: Calculated based on the proportion of subjects with huCART19-IL18 products that fail to meet the product release criteria, out of the number of subjects in whom manufacturing was attempted.

3 months
Proportion of manufactured products that meet the assigned dose
기간: 3 months

Cohort D: Calculated based on the proportion of subjects with huCART19-IL18 products that fail to meet the assigned dose, out of the number of subjects in whom manufacturing was attempted.

3 months

2차 결과 측정

결과 측정
측정값 설명
기간
Proportion of manufacturing products that meet the product release criteria
기간: 3 months

Cohorts A-C: Calculated based on the proportion of subjects with huCART19-IL18 products that fail to meet the product release criteria, out of the number of subjects in whom manufacturing was attempted. Will be evaluated separately by each disease-specific cohort.

3 months
Proportion of manufactured products that meet the assigned dose
기간: 3 months

Cohorts A-C: Calculated based on the proportion of subjects with huCART19-IL18 products that fail to meet the assigned dose, out of the number of subjects in whom manufacturing was attempted. Will be evaluated separately by each disease-specific cohort.

3 months
Incidence of Treatment-Emergent Adverse Events
기간: 3 months

Cohort D: Type, frequency and severity of adverse events as assessed by CTCAE V5.0.

3 months
Overall Response Rate (ORR)
기간: 3 months post-huCART19-IL18 infusion

NHL and CLL Patients: The proportion of subjects with CR or PR at Month 3 as compared to baseline.

3 months post-huCART19-IL18 infusion
Overall Response Rate (ORR)
기간: 1 month post-huCART19-IL18 infusion

ALL Patients: The proportion of subjects with CR/CRi/CR(MRD-) at Day 28 as compared to baseline

1 month post-huCART19-IL18 infusion
Best Overall Response (BOR)
기간: 12 months post-huCART19-IL18 infusion

NHL and CLL Patients: The proportion of subjects with a best overall disease response of CR or PR between Month 3 and Month 12, and prior to the start of new anticancer therapy.

12 months post-huCART19-IL18 infusion
Best Overall Response (BOR)
기간: 6 months post-huCART19-IL18 infusion

ALL Patients: The proportion of subjects with CR/CRi/CR(MRD-) by Month 6, and prior to the start of new anticancer therapy.

6 months post-huCART19-IL18 infusion
Duration of Response (DOR)
기간: Up to 15 years post-huCART19-IL18 infusion

NHL and CLL Patients: Duration from the date when CR/PR is first met at/after Month 3, to the date of relapse, death, or receipt of new anticancer therapy.

Up to 15 years post-huCART19-IL18 infusion
Duration of Remission (DOR)
기간: Up to 15 years post-huCART19-IL18 infusion

ALL Patients: Duration from the date when CR/CRi/CR(MRD-) is first met to the date of relapse, death or receipt of new anticancer therapy

Up to 15 years post-huCART19-IL18 infusion
Progression-Free Survival (PFS)
기간: 12 monthsUp to 15 years post-huCART19-IL18 infusion

NHL and CLL Patients: Duration of time from the huCART19-IL18 infusion to the date of the disease progression/relapse, death or receipt of new anticancer therapy

12 monthsUp to 15 years post-huCART19-IL18 infusion
Event-Free Survival (EFS)
기간: Up to 15 years post-huCART19-IL18 infusion

ALL Patients: Duration of time from the huCART19-IL18 infusion to the date of relapse/treatment failure, death or receipt of new anticancer therapy.

Up to 15 years post-huCART19-IL18 infusion
Overall Survival (OS)
기간: Up to 15 years post-huCART19-IL18 infusion

Duration of time from the huCART19-IL18 infusion to the date of death, for any reason

Up to 15 years post-huCART19-IL18 infusion
Characterize low level disease and B cell assessment in response to huCART19-IL18 cells by Flow Cytometry
기간: 12 months

Polychromatic flow cytometry-based assessment of leukemia and B cells, extent and duration of leukemic response

12 months
Characterize low level disease and B cell assessment in response to huCART19-IL18 cells by Next Gen Sequencing
기간: 12 months

Presence or absence of malignant B cells by Next-Generation Immunoglobulin heavy chain Sequencing (NGIS)

12 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Jakub Svoboda, MD, University of Pennsylvania

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 5월 6일

기본 완료 (추정된)

2036년 5월 1일

연구 완료 (추정된)

2036년 5월 1일

연구 등록 날짜

최초 제출

2020년 12월 11일

QC 기준을 충족하는 최초 제출

2020년 12월 21일

처음 게시됨 (실제)

2020년 12월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

키워드

기타 연구 ID 번호

  • 15420; IRB# 844955

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .